Transforming innovation in regenerative medicine
We are dedicated to incubating, launching, and building early-stage companies emerging from leading academic labs and research institutions in the field of regenerative medicine. We focus on therapies and technologies that can repair, replace, or regenerate organs, tissues, cells, and/or genes with the goal of treating the root causes of disease, rather than managing symptoms.
At Eos, we leverage our unique affiliation with leading research institutions to identify and nurture groundbreaking innovations in regenerative medicine. Our experienced team and strategic investments ensure that we not only build successful companies but also deliver sustainable value to our partners, to patients, and to the overall healthcare ecosystem.
We empower the future of regenerative medicine through strategic investments and innovation.
Balanced Portfolio
Our portfolio spans the breadth of the most promising and category-leading startups in the regenerative medicine field, across diseases and across technologies - from small molecules to cell and gene therapies to engineered biomaterials and enabling technologies.
Access to Key Networks
Our expansive network of individuals and firms provides our portfolio companies with timely strategic, technical, and operational expertise and advice.
Links to Leading Institutions
Our strong working relationship and collaboration with leading institutions, particularly with the Harvard Stem Cell Institute and the Harvard-affiliated research centers/hospitals over nearly 20 years, provides us unprecedented access to leading-edge ideas and technologies.
Network of World Renowned Advisors
Our scientific advisors are recognized leaders in their respective fields and many have founded and guided biotech companies to multi-billion dollar exits and market caps.
Regenerative medicine is not only the future of healthcare but is already a viable business. Just within the cell and gene therapy sector alone, there is an increasing number of transformative therapies entering the clinic.
CGT companies worldwide in 2024
Clinical trials worldwide in 2024
Increase in CGT clinical approvals in US and Europe vs 3 years ago*
Increase in CGT products in the clinical pipeline in US and Europe vs 3 years ago*
Explore our groundbreaking portfolio of companies pushing innovation in medicine.
